Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The Saccharomyces cerevisiae Sir2 protein is an NAD(+)-dependent histone deacetylase that plays a critical role in transcriptional silencing, genome stability, and longevity. A human homologue of Sir2, SIRT1, regulates the activity of the p53 tumor suppressor and inhibits apoptosis. The Sir2 deacetylation reaction generates two products: O-acetyl-ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of niacin/vitamin B(3). We show here that nicotinamide strongly inhibits yeast silencing, increases rDNA recombination, and shortens replicative life span to that of a sir2 mutant. Nicotinamide abolishes silencing and leads to an eventual delocalization of Sir2 even in G(1)-arrested cells, demonstrating that silent heterochromatin requires continual Sir2 activity. We show that physiological concentrations of nicotinamide noncompetitively inhibit both Sir2 and SIRT1 in vitro. The degree of inhibition by nicotinamide (IC(50) < 50 microm) is equal to or better than the most effective known synthetic inhibitors of this class of proteins. We propose a model whereby nicotinamide inhibits deacetylation by binding to a conserved pocket adjacent to NAD(+), thereby blocking NAD(+) hydrolysis. We discuss the possibility that nicotinamide is a physiologically relevant regulator of Sir2 enzymes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although NAM has been shown to be effective to increase NAD+ in tissues, it also exerts an inhibitory effect on sirtuin [88] and PARPs activity [89].”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [88]
In the citing paper
“Deacetylation of PGC-1α is required to sequester it in the nucleus and this cellular redistribution is prevented by nicotinamide, a potent SIRT1 inhibitor [64].”
From PGC-1α in aging and anti-aging interventions (2009) · cites this paper as [64]
Citations
Cites
Genomic Expression Programs in the Response of Yeast Cells to Environmental Changes
Gasch, A. P., Spellman, P. T., Kao, C. M., Carmel-Harel, O., Eisen, M. B., Storz, G., Botstein, D., & Brown, P. O. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4241 · Cited by 4,815
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Kaeberlein, M., McVey, M., & Guarente, L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2570 · Cited by 2,253
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Lin, S.-J., Defossez, P.-A., & Guarente, L. (2000) · Science · doi:10.1126/science.289.5487.2126 · Cited by 1,775
Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans
Tissenbaum, H. A., & Guarente, L. (2001) · Nature · doi:10.1038/35065638 · Cited by 1,603
Extrachromosomal rDNA circles—a cause of aging in yeast
Sinclair, D. A., & Guarente, L. (1997) · Cell · doi:10.1016/s0092-8674(00)80493-6 · Cited by 1,500
Self-citationPosition effect at S. cerevisiae telomeres: Reversible repression of Pol II transcription
Gottschling, D. E., Aparicio, O. M., Billington, B. L., & Zakian, V. A. (1990) · Cell · doi:10.1016/0092-8674(90)90141-z · Cited by 1,345
Research works printed but not linked: 1
- Gasser, 1998, Novartis Found. Symp., 214, 114
Cited by
Items 201–300 of 1,000
Shinozaki, S., Chang, K., Sakai, M., Shimizu, N., Yamada, M., Tanaka, T., Nakazawa, H., Ichinose, F., Yamada, Y., Ishigami, A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005375 · Cited by 140
Metabonomic Investigations of Aging and Caloric Restriction in a Life-Long Dog Study
Wang, Y., Lawler, D., Larson, B., Ramadan, Z., Kochhar, S., Holmes, E., & Nicholson, J. K. (2007) · Journal of Proteome Research · doi:10.1021/pr060685n · Cited by 143
NAD metabolism: Role in senescence regulation and aging
Chini, C. C. S., Cordeiro, H. S., Tran, N. L. K., & Chini, E. N. (2023) · Aging Cell · doi:10.1111/acel.13920 · Cited by 167
“Studies suggest that NAM is the main vitamin B3-derived NAD + precursor in mammals, and it also regulates NAD-consuming enzymes by inhibiting NAD-binding sites (Bitterman et al., 2002; Zeidler, Chini, et al., 2022).”
BackgroundChemical Activation of Sir2-Dependent Silencing by Relief of Nicotinamide Inhibition
Sauve, A. A., Moir, R. D., Schramm, V. L., & Willis, I. M. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.032 · Cited by 161
Katic, M., Kennedy, A. R., Leykin, I., Norris, A., McGettrick, A., Gesta, S., Russell, S. J., Bluher, M., Maratos‐Flier, E., & Kahn, C. R. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00346.x · Cited by 141
Emerging Roles for SIRT5 in Metabolism and Cancer
Bringman, L. R., Guo, A. H., Lyssiotis, C. A., & Lombard, D. B. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7264 · Cited by 144
Cellular and molecular effects of sirtuins in health and disease
Horio, Y., Hayashi, T., Kuno, A., & Kunimoto, R. (2011) · Clinical Science · doi:10.1042/cs20100587 · Cited by 135
Mould, A. W., Tonks, I. D., Cahill, M. M., Pettit, A. R., Thomas, R., Hayward, N. K., & Kay, G. F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11232 · Cited by 136
Liu, J., & Ames, B. N. (2005) · Nutritional Neuroscience · doi:10.1080/10284150500047161 · Cited by 137
“Nicotinamide is also an inhibitor of polyADPribose polymerase and the sir 2 enzymes, which are NAD(þ)-dependent protein deacetylases that play key roles in transcriptional regulation, DNA repair, and life span regulation (Anderson et al. 1999, Bitterman et al. 2002).”
BackgroundNaia, L., Rosenstock, T. R., Oliveira, A. M., Oliveira-Sousa, S. I., Caldeira, G. L., Carmo, C., Laço, M., Hayden, M. R., Oliveira, C. R., & Rego, A. C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0048-3 · Cited by 143
Bedalov, A., Hirao, M., Posakony, J., Nelson, M., & Simon, J. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.19.7044-7054.2003 · Cited by 135
“, nicotinamide) which may inhibit Sir2p deacetylase activity (2, 5) were proposed as explanations for this discrepancy.”
BackgroundYang, S. J., Choi, J. M., Kim, L., Park, S. E., Rhee, E., Lee, W., Oh, K. W., Park, S. W., & Park, C.-Y. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.09.004 · Cited by 145
“In contrast, NAM inhibits Sirt1 activity in vitro and in vivo under various conditions by (1) non-competitively inhibiting conformational changes in sirtuin in response to NAD binding and NAD cleavage in the C pocket of sirtuin and (2) competitively against NAD for binding to the C pocket of sirtuin [24–26].”
BackgroundKelly, G. S. (2010) · PubMed · Cited by 172
WANG, J., KIM, T. H., AHN, M. Y., LEE, J., JUNG, J. H., CHOI, W. S., LEE, B. M., YOON, K. S., YOON, S., & KIM, H. S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1534 · Cited by 134
Sirtuin deacylases: a molecular link between metabolism and immunity
Preyat, N., & Léo, O. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1112557 · Cited by 143
“Nam, the end-product of all enzymatic reactions catalyzed by NAD -consuming enzymes, including sirtuins, represents a NAD precursor and an endogenous, noncompetitive sirtuin inhibitor [19].”
BackgroundSIR Proteins and the Assembly of Silent Chromatin in Budding Yeast
Kueng, S., Oppikofer, M., & Gasser, S. M. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-021313-173730 · Cited by 129
New Paradigms in the Pathogenesis of Chronic Obstructive Pulmonary Disease I
MacNee, W., & Tuder, R. M. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200905-027ds · Cited by 132
“Metabolic nitocinamide adenines, nucleotide (NAD1)dependent histone/protein deacetylases (sirtuins), are type III histone deacetylases (HDAC) and are structurally different from other HDACs and inhibited by different compounds (60); they play an important role in a variety of processes, including stress resistance, me…”
Small molecule regulation of Sir2 protein deacetylases
Grubisha, O., Smith, B. C., & Denu, J. M. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04862.x · Cited by 129
“Originally, it was believed that nicotinamide bound to an allosteric site and consequently inhibited Sir2 activity [ 40 ].”
BackgroundAlsford, S., Kawahara, T., Isamah, C., & Horn, D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05553.x · Cited by 138
“, 2001), could reflect competition with Sir2 for a substrate or ligand, such as NAD+, or production of nicotinamide, a Sir2 inhibitor (Bitterman et al., 2002).”
Komatsu, M., Kanda, T., Urai, H., Kurokochi, A., Kitahama, R., Shigaki, S., Ono, T., Yukioka, H., Hasegawa, K., Tokuyama, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26882-8 · Cited by 126
Marques, C., Hadjab, F., Porcello, A., Lourenço, K., Scaletta, C., Abdel-Sayed, P., Hirt‐Burri, N., Applegate, L. A., & Laurent, A. E. (2024) · Antioxidants · doi:10.3390/antiox13040425 · Cited by 142
“Importantly, these metabolic proteins are involved in several skin-relevant cellular functions and processes, including aging, UV damage responses, oxidative stress, inflammation, and wound repair [22,24,25].”
Mitochondrial Sirtuins in the Regulation of Mitochondrial Activity and Metabolic Adaptation
Lombard, D. B., Tishkoff, D. X., & Bao, J. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-21631-2_8 · Cited by 122
“Sirtuin activity can be repressed by NADH and by a product of the sirtuin deacetylase reaction, nicotinamide (NAM) (Bitterman et al. 2002; Lin et al. 2004).”
BackgroundCell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Li, F., Chong, Z., & Maiese, K. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776361058 · Cited by 127
SIRT1 regulates macrophage self‐renewal
Imperatore, F., Maurizio, J., Aguilar, S. V., Busch, C. J., Favret, J., Kowenz‐Leutz, E., Cathou, W., Gentek, R., Perrin, P., Leutz, A., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201695737 · Cited by 141
“NAM is generated as a by-product of sirtuin deacetylase activity and blocks further catalysis in a negative feedback loop (Bitterman et al , 2002; Avalos et al , 2005).”
Nicotinamide enhances mitochondria quality through autophagy activation in human cells
Kang, H. T., & Hwang, E. S. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00487.x · Cited by 125
“orthologue, SIRT1, both members of the NAD-dependent histone deacetylase family (Luo et al., 2001; Bitterman et al., 2002).”
BackgroundMethodHepatic transcriptional responses to fasting and feeding
Bideyan, L., Nagari, R., & Tontonoz, P. (2021) · Genes & Development · doi:10.1101/gad.348340.121 · Cited by 126
“SIRT1 is activated in response to an increase in the NAD+/NADH ratio during fasting (Bitterman et al. 2002).”
BackgroundChemical regulation of epigenetic modifications: Opportunities for new cancer therapy
Zheng, Y. G., Wu, J., Chen, Z., & Goodman, M. (2008) · Medicinal Research Reviews · doi:10.1002/med.20120 · Cited by 123
“It inhibits yeast silencing, increases rDNA recombination, and shortens replicative life.(264) Grozinger et al.”
Sirtuins: NAD+-dependent deacetylase mechanism and regulation
Sauve, A. A., & Youn, D. Y. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.10.003 · Cited by 136
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Song, Q., Zhou, X., Xu, K., Liu, S., Zhu, X., & Yang, J. J. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.08.008 · Cited by 139
“Nonetheless, due to their potential side effects, such as fl ushing and inhibiting PARPs and sirtuins, both NA and NAM should be used with caution [159].”
BackgroundLithocholic acid binds TULP3 to activate sirtuins and AMPK to slow down ageing
Qu, Q., Chen, Y., Wang, Y., Wang, W., Long, S., Yang, H.-Y., Wu, J., Li, M., Tian, X., Wei, X., et al. (2024) · Nature · doi:10.1038/s41586-024-08348-2 · Cited by 141
The Current State of NAD+‐Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets
Schiedel, M., Robaa, D., Rumpf, T., Sippl, W., & Jung, M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21436 · Cited by 137
Targeting Cardiovascular Disease With Novel SIRT1 Pathways
Chong, Z. Z., Wang, S., Shang, Y. C., & Maiese, K. (2012) · Future Cardiology · doi:10.2217/fca.11.76 · Cited by 123
“The decreased NAD+/NADH ratio as well as nicotinamide production can inhibit SIRT1 activity [2].”
BackgroundExcessive HDAC activation is critical for neurodegeneration in the rd1 mouse
Sancho-Pelluz, J., Alavi, M. V., Sahaboglu, A., Kustermann, S., Farinelli, P., Azadi, S., van Veen, T., Romero, F. J., Paquet-Durand, F., & Ekström, P. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.4 · Cited by 124
“NAM is a constituent of the culturing medium and present at about 22mM, which should be less than half the reported IC50 value in cell-free studies.(45) Explants were cultured until P11 for short-term cultures (P5þ 2þ 4), or until P28, for long-term cultures (P5þ 2þ 21).”
BackgroundHathorn, T., Snyder-Keller, A., & Messer, A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.017 · Cited by 123
Yeast sirtuins and the regulation of aging
Wierman, M. B., & Smith, J. S. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12115 · Cited by 128
“The deacetylation activity of Sir2 and other sirtuins is strongly inhibited by NAM in vitro (Landry et al., 2000), and growing yeast in culture with 5 mM NAM inhibits silencing at the rDNA, telomeres, and mating-type loci (Bitterman et al., 2002).”
InfluentialAccelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD)
MacNee, W. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370819 · Cited by 137
The conserved role of sirtuins in chromatin regulation
Vaquero, A. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082675av · Cited by 117
“One mechanism, found from yeast to man, is the non-competitive effect of excess free nicotinamide, which is released upon NAD+ catabolism (Bitterman et al., 2002).”
BackgroundSirtuin‐independent effects of nicotinamide on lifespan extension from calorie restriction in yeast
Tsuchiya, M., Dang, N., Kerr, E. O., Hu, D., Steffen, K. K., Oakes, J. A., Kennedy, B. K., & Kaeberlein, M. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00240.x · Cited by 114
“It is therefore surprising that growth on 5 mM nicotinamide, which is sufficient to inhibit Sir2 in vivo (Bitterman et al., 2002), fails to phenocopy the severe lifespan defect of hst3∆ hst4∆ cells.”
BackgroundStructural Insights into Intermediate Steps in the Sir2 Deacetylation Reaction
Hawse, W. F., Hoff, K. G., Fatkins, D. G., Daines, A. M., Zubkova, O. V., Schramm, V. L., Zheng, W., & Wolberger, C. (2008) · Structure · doi:10.1016/j.str.2008.05.015 · Cited by 125
“, 2002)Yeast treated with nicotinamide show a decreased level of transcriptional silencing, similar to that observed when Sir2 is deleted (Bitterman et al., 2002).”
BackgroundInfluentialCardiac HDAC6 catalytic activity is induced in response to chronic hypertension
Lemon, D. D., Horn, T. R., Cavasin, M. A., Jeong, M. Y., Haubold, K. W., Long, C. S., Irwin, D. C., McCune, S. A., Chung, E., Leinwand, L. A., et al. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.04.005 · Cited by 115
“Class I HDACs (HDACs 1, 2, 3 and 8) are related to yeast RPD3, class II HDACs (HDACs 4, 5, 6, 7, 9 and 10) to yeast HDA1, and class III HDACs (SirT1–7) to yeast Sir2.”
Nampt/PBEF/Visfatin: A regulator of mammalian health and longevity?
Yang, H., Lavu, S., & Sinclair, D. A. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.06.003 · Cited by 120
“The first clue to the potential importance of NAM in sirtuin biology was the observation that sirtuins are inhibited by NAM in a non-competitive fashion (Bitterman et al., 2002; Landry et al., 2000a), the implication being that NAM does not compete with NAD+ for binding but binds to a distinct site (Avalos et al.”
BackgroundInfluentialSelf-citationAging and induced senescence as factors in the pathogenesis of lung emphysema
Karrasch, S., Holz, O., & Jörres, R. A. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.04.013 · Cited by 114
“Within the group of HDACs, sirtuins maintain a special position since they are structurally different from other HDACs and are inhibited by different compounds.(189) Sirtuins act on histones similarly to other HDACs thereby mediating gene silencing.”
BackgroundLiu, Y., Smith, P. W., & Jones, D. R. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00940-06 · Cited by 122
“Nicotinamide (NAM) is a specific negative regulator of class III HDACs (6).”
BackgroundInfluentialNε-Thioacetyl-lysine: A multi-facet functional probe for enzymatic protein lysine Nε-deacetylation
Fatkins, D. G., Monnot, A. D., & Zheng, W. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.075 · Cited by 126
Insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1
Wang, S., Jiang, B., Zhang, T., Liu, L., Wang, Y., Wang, Y., Chen, X., Lin, H., Zhou, L., Xia, Y., et al. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002243 · Cited by 131
“2-fold in HEK293T cells after treatment with nicotinamide (NAM), an inhibitor of the SIRT family deacetylases [24,25], and trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC) I and II (Fig 1A) [26,27].”
BackgroundChanges in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats
Braidy, N., Guillemin, G. J., Mansour, H., Chan‐Ling, T., & Grant, R. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08366.x · Cited by 112
Berger, F., Lau, C., & Ziegler, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609211104 · Cited by 104
NAD+ as a Signaling Molecule Modulating Metabolism
Canto, C., & Auwerx, J. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.010439 · Cited by 108
“inhibited in a non-competitive fashion by NAM (Bitterman et al., 2002).”
BackgroundInvestigating the Sensitivity of NAD+-dependent Sirtuin Deacylation Activities to NADH
Madsen, A. S., Andersen, C., Daoud, M., Anderson, K. A., Laursen, J. S., Chakladar, S., Huynh, F. K., Colaço, A. R., Backos, D. S., Fristrup, P., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.668699 · Cited by 110
Metabolic effects of resveratrol: Addressing the controversies
Bitterman, J. L., & Chung, J. H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1808-8 · Cited by 109
“This screen involved the use of a fluorescently labeled peptide substrate, called Fluor-de-Lys, mimicking a short sequence from p53 that had been shown to be deacetylated by Sirt1 [24].”
Structure and autoregulation of the yeast Hst2 homolog of Sir2
Zhao, K., Chai, X., Clements, A. M., & Marmorstein, R. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb978 · Cited by 124
“Reactions were quenched by addition of 10 mM nicotinamide inhibito”
MethodFatty Liver and Fibrosis in Glycine N -Methyltransferase Knockout Mice Is Prevented by Nicotinamide
Varela-Rey, M., Martínez-López, N., Fernández-Ramos, D., Embade, N., Calvisi, D. F., Woodhoo, A., Rodríguez, J., Fraga, M. F., Julve, J., Rodríguez-Millán, E., et al. (2010) · Hepatology · doi:10.1002/hep.23639 · Cited by 102
“Moreover, the finding that the administration to GNMT -KO mice of NAM, an inhibitor of SIRT1 activity (28), prevented rather than aggravated the abnormal expression of CD36, ADFP, PARP α and PARP α further supports the conclusion that the development of steatosis in GNMT -KO mice is independent of…”
Sir2 and calorie restriction in yeast: A skeptical perspective
Kaeberlein, M. R., & Powers, R. W. (2007) · Ageing Research Reviews · doi:10.1016/j.arr.2007.04.001 · Cited by 125
“cerevisiae for which the genome has been sequenced (Brachmann et al., 1998; Cherry et al., 1997).”
BackgroundDesign and synthesis of compounds that extend yeast replicative lifespan
Yang, H., Baur, J. A., Chen, A., Miller, C., & Sinclair, D. A. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2006.00259.x · Cited by 107
“Lifespan measurements were performed using PSY316ATα as previously described (Bitterman et al., 2002).”
MethodSelf-citationGhosh, S., & Feany, M. B. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh214 · Cited by 106
Human Sirtuin Regulators: The “Success” Stories
Curry, A. M., White, D. S., Donu, D., & Cen, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.752117 · Cited by 116
“Before 2005, many small molecule regulators targeting sirtuins showed modest potency, isoform selectivity, and solubility (Bedalov et al., 2001; Grozinger et al., 2001; Bitterman et al., 2002; Mai et al., 2005; Olaharski et al., 2005; Porcu and Chiarugi, 2005).”
BackgroundBrandauer, J., Vienberg, S. G., Andersen, M. A., Ringholm, S., Risis, S., Larsen, P. S., Kristensen, J. M., Frøsig, C., Leick, L., Fentz, J., et al. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.259515 · Cited by 104
“Because NAM inhibits SIRT activity (Bitterman et al. 2002), NAM must be reconverted to NAD to maintain SIRT activity and mitochondrial metabolism.”
BackgroundNicotinamide extends replicative lifespan of human cells
Kang, H. T., Lee, H. I., & Hwang, E. S. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00234.x · Cited by 105
“Lee, unpublished result), possibly through a direct inhibition of SIRT1 (Bitterman et al., 2002), a decetylase targeting p53 (Luo et al.”
BackgroundRotili, D., Tarantino, D., Nebbioso, A., Paolini, C., Huidobro, C., Lara, E., Mellini, P., Lenoci, A., Pezzi, R., Botta, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011614 · Cited by 108
A novel assay for replicative lifespan in
JAROLIM, S., MILLEN, J., HEEREN, G., LAUN, P., GOLDFARB, D., & BREITENBACH, M. (2004) · FEMS Yeast Research · doi:10.1016/j.femsyr.2004.06.015 · Cited by 104
“Pnc1p positively regulates Sir2p-mediated silencing and longevity by preventing the accumulation of nicotinamide during stress [20,23,24].”
BackgroundGlaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Williams, P. A., Harder, J. M., & John, S. W. M. (2017) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000767 · Cited by 102
The ATAC acetyl transferase complex controls mitotic progression by targeting non‐histone substrates
Orpinell, M., Fournier, M. L., Riss, A., Nagy, Z., Krebs, A. R., Frontini, M., & Tora, L. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.125 · Cited by 108
“Next, we H4K16ac Mock Ada2a KD T el op ha se A na ph as e M et ap ha se In te rp ha se Ada3 KD T el op ha se A na ph as e M et ap ha se In te rp ha se Acetyl-tubulin Mock Ada2a KD Ada3 KD M oc k H3 H4K16ac Tubulin Ac-tubulin A da 2a K D A da 3 K D T el op ha se A na ph as e M et ap ha se Mock Ada2a KD Ada3 KD SIRT2 NA…”
MethodInfluentialSmith, B. C., & Denu, J. M. (2006) · Biochemistry · doi:10.1021/bi052014t · Cited by 101
“One line of evidence for an α-1’-O-alkylamidate is the ability of nicotinamide, a potent product inhibitor (15,16,38-40), to rapidly react with the enzyme:ADP-ribose:acetylated protein intermediate, regenerating NAD+ and acetylated protein by a process dubbed the nicotinamide exchange (or transglycosidation) reaction…”
BackgroundMerrick, C. J., & Duraisingh, M. T. (2007) · Eukaryotic Cell · doi:10.1128/ec.00114-07 · Cited by 115
“Several inhibitors and activators of ScSir2 have been identified, including the inhibitors nicotinamide (5), sirtinol (25), and splitomicin (3) and the activators isonicotinamide (52) and resveratrol (33).”
BackgroundAlegre, G. F. S., & Pastore, G. M. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00475-y · Cited by 101
Real-time analysis of double-strand DNA break repair by homologous recombination
Hicks, W. M., Yamaguchi, M., & Haber, J. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019660108 · Cited by 111
“This modification did not alter the heterochromatic state ofHML because these cells were Ura unless desilenced by nicotinamide addition (62).”
Topark-Ngarm, A., Golonzhka, O., Peterson, V. J., Brian, B., Martinez, B., Crofoot, K., Filtz, T. M., & Leid, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602776200 · Cited by 97
Wang, J., Fivecoat, H. C., Ho, L., Pan, Y., Ling, E., & Pasinetti, G. M. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.015 · Cited by 105
Lin, S. S., Manchester, J. K., & Gordon, J. I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212818200 · Cited by 91
Are poly(ADP‐ribosyl)ation by PARP‐1 and deacetylation by Sir2 linked?
Zhang, J. (2003) · BioEssays · doi:10.1002/bies.10317 · Cited by 98
The Protein Level of PGC-1α, a Key Metabolic Regulator, Is Controlled by NADH-NQO1
Adamovich, Y., Shlomai, A., Tsvetkov, P., Umansky, K. B., Reuven, N., Estall, J. L., Spiegelman, B. M., & Shaul, Y. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01672-12 · Cited by 95
“The PGC-1 acetylation level under NQO1 depletion was similar to that in control C2C12 cells treated with nicotinamide (NAM), a histone deacetylase inhibitor (65).”
MethodSmith, K., Kothe, G. O., Matsen, C. B., Khlafallah, T. K., Adhvaryu, K. K., Hemphill, M., Freitag, M., Motamedi, M. R., & Selker, E. U. (2008) · Epigenetics & Chromatin · doi:10.1186/1756-8935-1-5 · Cited by 99
“We first used a plating assay to test the effect of the Class III (sirtuin) HDAC inhibitor nicotinamide [45] on TPE and also on expression of an interstitial allele of hph allele that was silenced by DNA methylation spreading from flanking sequences that had been subjected to RIP [46].”
MethodA forkhead in the road to longevity: the molecular basis of lifespan becomes clearer
Morris, B. J. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000173509.45363.dd · Cited by 98
Jia, H., Li, X., Gao, H., Feng, Z., Li, X., Zhao, L., Jia, X., Zhang, H., & Liu, J. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21650 · Cited by 94
“Nicotinamide is also an inhibitor of polyADPribose polymerase and the sir2 enzymes, NAD(1)dependent protein deacetylases that play key roles in transcriptional regulation, DNA repair, and life span regulation (Anderson et al., 1999; Bitterman et al., 2002).”
BackgroundLOU, Y., WANG, Z., XU, Y., Zhou, P. H., Cao, J., Li, Y., Chen, Y., Sun, J., & Fu, L. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2291 · Cited by 100
“Sirt1 catalyzes the deacetylation of numerous proteins and generates nicotinamide (NIC) as a by-product, which then functions as a negative regulator of Sirt1 activity (28,29).”
Kuhn, A. N., van Santen, M. A., Schwienhorst, A., Urlaub, H., & Lührmann, R. (2009) · RNA · doi:10.1261/rna.1332609 · Cited by 95
Kratz, E. M., Sołkiewicz, K., Kubis-Kubiak, A., & Piwowar, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020630 · Cited by 105
NAD+-dependent histone deacetylases (sirtuins) as novel therapeutic targets
Schemies, J., Uciechowska, U., Sippl, W., & Jung, M. (2009) · Medicinal Research Reviews · doi:10.1002/med.20178 · Cited by 107
Diversity in the Sir2 family of protein deacetylases
Buck, S. W., Gallo, C. M., & Smith, J. S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0903424 · Cited by 94
“Sinclair laboratory [25] found that inclusion of NAM in the”
BackgroundMethodInfluentialVassallo, P. F., Simoncini, S., Ligi, I., Chateau, A.-L., Bachelier, R., Robert, S., Morere, J., Fernandez, S., Guillet, B., Marcelli, M., et al. (2014) · Blood · doi:10.1182/blood-2013-02-484956 · Cited by 94
“Interestingly, addition of NAM, a competitive inhibitor of SIRT1 activity, 24,25 counteracted the bene fi cial effect of SIRT1 overexpression on the For personal use only. on December 13, 2017. by guest www.bloodjournal.org From senescent phenotype of PT-ECFCs (Figure 4C) and was associated…”
BackgroundNAD+ therapy in age-related degenerative disorders: A benefit/risk analysis
Braidy, N., & Liu, Y. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110831 · Cited by 103
Li, F., Dong, J., Pan, X., Oum, J.-H., Boeke, J. D., & Lee, S. E. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.028 · Cited by 106
Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases
Heltweg, B., Dequiedt, F., Verdin, E. M., & Jung, M. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00276-8 · Cited by 110
“For the unspecific sirtuin inhibitor nicotinamide [26], we were able to observe an inhibition of the conversion of 2 at 30 lM (21% inhibition) and 100 lM (44% inhibition ) (data not shown).”
The Flavoring Agent Dihydrocoumarin Reverses Epigenetic Silencing and Inhibits Sirtuin Deacetylases
Olaharski, A. J., Rine, J., Marshall, B. L., Babiarz, J., Zhang, L., Verdin, E., & Smith, M. T. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010077 · Cited by 93
“cerevisiae by 30% [7], and Sir2p inhibition by nicotinamide mimics this effect [8].”
BackgroundA chemical probe toolbox for dissecting the cancer epigenome
Shortt, J., Ott, C. J., Johnstone, R. W., & Bradner, J. E. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.148 · Cited by 98
Emerging Therapeutic Potential of SIRT6 Modulators
Fiorentino, F., Mai, A., & Rotili, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00601 · Cited by 98
Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule
Elhassan, Y., Philp, A., & Lavery, G. G. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00092 · Cited by 101
“Nam acts as an NAD+ precursor, increasing SIRT1 activity (below a threshold of sirtuin inhibition), or, conversely, a SIRT1 inhibitor, depending on the specific pathophysiologic state [84, 85].”
BackgroundThe CD38 glycohydrolase and the NAD sink: implications for pathological conditions
Zeidler, J. D., Hogan, K. A., Agorrody, G., Peclat, T., Kashyap, S., Kanamori, K. S., Gomez, L. S., Mazdeh, D. Z., Warner, G. M., Thompson, K. L., et al. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00451.2021 · Cited by 97
Mitochondrial longevity pathways
Vendelbo, M. H., & Nair, K. S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.029 · Cited by 93
Therapeutic potential of boosting NAD+ in aging and age-related diseases
Aman, Y., Qiu, Y., Tao, J., & Fang, E. F. (2018) · Translational Medicine of Aging · doi:10.1016/j.tma.2018.08.003 · Cited by 82
NMNAT Expression and its Relation to NAD Metabolism
N. Jayaram, H., Kusumanchi, P., & A. Yalowitz, J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795590138 · Cited by 87
“Nicotinamide abolishes silencing and leads to an eventual delocalization of Sir2 even in G1-arrested cells, demonstrating that silent heterochromatin requires continual Sir2 activity [94].”
BackgroundChoudhury, G., & MacNee, W. (2016) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2016.1214948 · Cited by 101
Frederick, D. W., Davis, J. G., Dávila, A., Agarwal, B., Michan, S., Puchowicz, M. A., Nakamaru-Ogiso, E., & Baur, J. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.579565 · Cited by 88
“This is of interest because it has been proposed that NAM acts as a feedback inhibitor of NAD-dependent enzymes in the concentration range that we have detected (1, 45, 46).”
BackgroundLi, Y., He, X., Li, Y., He, J., Anderstam, B., Andersson, G., & Lindgren, U. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.480 · Cited by 96
“In contrast, the IC50 of NAM on human Sirt1 is shown to be less than 50mM,((17)) and over 95% inhibition of Sirt1 occurred at the presence of 160mM NAM in mouse cells.”
BackgroundC/EBPε mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice
Kyme, P., Thoennissen, N. H., Tseng, C. W., Thoennissen, G. B., Wolf, A. J., Shimada, K., Krug, U. O., Lee, K., Müller-Tidow, C., Berdel, W. E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62070 · Cited by 86
Furuyama, T., Banerjee, R., Breen, T. R., & Harte, P. J. (2004) · Current Biology · doi:10.1016/j.cub.2004.09.060 · Cited by 94
Vitamin B3 and sirtuin function
Denu, J. M. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.07.004 · Cited by 100
Pontiki, E. A., & Hadjipavlou‐Litina, D. (2011) · Medicinal Research Reviews · doi:10.1002/med.20200 · Cited by 91
“Nicotinamide and its analogs Nicotinamide, a reaction product, is the endogenous and allosteric noncompetitive inhibitor, which is formed from NAD(1) during the catalysis mechanism.(56) It inhibits SIRTs by binding to a conserved pocket adjacent to the NAD(1)-binding pocket, thereby blocking NAD(1) hydrolysis.”
BackgroundOn Acetyl-CoA as a Gauge of Cellular Metabolic State
Cai, L., & Tu, B. P. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010769 · Cited by 83
“Moreover, the sirtuins are also subject to inhibition by nicotinamide (Bitterman et al. 2002).”
BackgroundNicotinamide ribose ameliorates cognitive impairment of aged and Alzheimer’s disease model mice
Xie, X. M., Gao, Y., Zeng, M., Wang, Y., Wei, T.-F., Lu, Y., & Zhang, W. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0346-8 · Cited by 91
Metadata
- Authors
- Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sinclair, David A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 277
- Issue
- 47
- Pages
- 45099-45107
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2167990179
- Cited by
- 1,002
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 32 · 2023: 33 · 2022: 36 · 2021: 41 · 2020: 38 · 2019: 39 · 2018: 47 · 2017: 43 · 2016: 43 · 2015: 58 · 2014: 40 · 2013: 58 · 2012: 56
- FWCI
- 21.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6554 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG11972-01)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- nicotinamide, Sir2, SIRT1, transcriptional silencing, heterochromatin, replicative lifespan, aging, NAD+ hydrolysis, enzyme inhibition, p53, apoptosis, histone deacetylation
- MeSH terms
- Aging, DNA, Ribosomal, Genes, Fungal, Histone Deacetylases, Humans, Life Expectancy, Luminescent Proteins, Models, Biological, Niacinamide, Recombinant Fusion Proteins, Recombination, Genetic, Saccharomyces cerevisiae, Molecular Structure, Telomere, Gene Silencing, Sirtuins, Silent Information Regulator Proteins, Saccharomyces cerevisiae, Green Fluorescent Proteins, Sirtuin 1, Sirtuin 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.